Fulcrum Therapeutics News

Fulcrum Upgraded by Goldman Sachs Ahead of Phase 3 Data

Seeking Alpha17:52 ET

Fulcrum Therapeutics Analyst Ratings

Benzinga16:20 ET

Buy Rating Upheld for Fulcrum Therapeutics Amid Sanofi Partnership and Upcoming Trial Catalysts

TipRanks13:05 ET

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)

TipRanksMar 19 01:50 ET

Fulcrum Therapeutics Analyst Ratings

BenzingaMar 13 12:29 ET

Strong Buy Rating for Fulcrum Therapeutics Amidst Promising Clinical Progress and Financial Stability

TipRanksMar 1 01:04 ET

Fulcrum Therapeutics Analyst Ratings

BenzingaFeb 28 10:43 ET

Oppenheimer Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)

TipRanksFeb 28 07:47 ET

Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC), Ligand Pharma (LGND) and Alphatec Holdings (ATEC)

TipRanksFeb 28 07:32 ET

Stifel Nicolaus Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)

TipRanksFeb 9 08:29 ET

Fulcrum Therapeutics Analyst Ratings

BenzingaJan 26 09:27 ET

Fulcrum Therapeutics Analyst Ratings

BenzingaJan 25 09:07 ET

Fulcrum Therapeutics Receives Buy Rating Amidst Promising Clinical Progress and Anticipated Data Readouts

TipRanksNov 10, 2023 06:30 ET

Fulcrum Therapeutics Analyst Ratings

BenzingaSep 25, 2023 05:00 ET

Hold Rating on Fulcrum Therapeutics: Potential Growth and Challenges Ahead

TipRanksSep 25, 2023 02:25 ET

Fulcrum Therapeutics Analyst Ratings

BenzingaAug 23, 2023 06:17 ET

H.C. Wainwright Upgrades Fulcrum Therapeutics (FULC) to a Buy

TipRanksAug 23, 2023 06:15 ET

Bank of America Securities Remains a Sell on Fulcrum Therapeutics (FULC)

TipRanksAug 23, 2023 04:55 ET

Oppenheimer Reiterates Outperform on Fulcrum Therapeutics, Maintains $16 Price Target

BenzingaAug 22, 2023 10:09 ET

Fulcrum Therapeutics (NASDAQ:FULC) Skyrockets After FDA Lifts Clinical Hold on Sickle Cell Disease Candidate

TipRanksAug 22, 2023 09:10 ET